Search
Palovarotene
go.drugbank.com/drugs/DB05467Approved, tendons) are replaced with bone. … [L40010] On August 16, 2023, palovarotene was also approved by the FDA for the management of HO associated with FOP.[L47845]
Holcus lanatus pollen
go.drugbank.com/drugs/DB10395ApprovedHolcus lanatus pollen is mainly used in allergenic testing.
Mixtures: Mixture of Standardized and Non-Standardized Coastal Grasses, Mixture of Twenty-Two Standardized and Non-Standardized GrassesCategories: Non-Standardized Pollen Allergenic ExtractCorticorelin ovine triflutate
go.drugbank.com/drugs/DB09067ApprovedCorticorelin, available commercially as corticorelin ovine triflutate (tradename Acthrel), is a synthetic form of the peptide human corticotropin-releasing hormone (hCRH), a potent stimulator of adrenocorticotropic … If corticorelin injection results in an increase of plasma ACTH and cortisol, the patient is diagnosed with Cushing's disease.
Dextrothyroxine
go.drugbank.com/drugs/DB00509ApprovedWithdrawnThyroxine is peripherally deiodinated to form triiodothyronine which exerts a broad spectrum of stimulatory effects on cell metabolism. … Thyroxine is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines (diiodotyrosine) in the thyroglobulin.
Omacetaxine mepesuccinate
go.drugbank.com/drugs/DB04865ApprovedInvestigationalWithdrawnThen in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. … In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA.
Benfluorex
go.drugbank.com/drugs/DB09022ApprovedWithdrawnThe European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009. … This recommendation was based on the risks (especially fenfluramine-like cardiovascular side-effects) outweighing the benefits.
Categories: Drugs Used in DiabetesBrentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigationalFood and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. … Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE).
Sunvozertinib
go.drugbank.com/drugs/DB18925Investigational[A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor … Sunvozertinib is an irreversible and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Synonyms: 2-Propenamide, N-[5-[[4-[[5-chloro-4-fluoro-2-(1-hydroxy-1- methylethyl)phenyl]amino]-2-pyrimidinyl]amino]-2-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-4-methoxyphenyl]-, N-{5-[(4-{[5-chloro-4-fluoro-2-(1-hydroxy-1-methylethyl)phenyl]amino}pyrimidin-2-yl)amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl}prop-2-enamideCysteamine
go.drugbank.com/drugs/DB00847ApprovedInvestigational[L15606,L15616] In particular, cystine deposits on the eye can cause significant discomfort throughout the day and require frequent treatment with eye drops, typically every waking hour. … [L15611] On August 25th 2020, the first ophthalmic solution for cystinosis requiring only 4 daily treatments was granted FDA approval.
Margetuximab
go.drugbank.com/drugs/DB14967ApprovedInvestigational[A225751] The introduction of [trastuzumab] improved patient outcomes in HER2-positive breast cancer, but notably depended substantially on polymorphisms in the FcγRIIIA/CD16A receptor, whereby low affinity … [A225751, A225756, A225766, A191829, L27986] Margetuximab binds to the same epitope on the HER2 extracellular domain and induces the same effects as [trastuzumab].